Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

322 ARTÍCULOS , VIENDO DEL 301 AL 315

[Alzheimer's disease]

Jedidi H, Jedidi Z, Salmon E.

Rev Med Liege. 2010 Mar;65(3):163-8.

Why pleiotropic interventions are needed for Alzheimer's disease

Frautschy SA, Cole GM.

Mol Neurobiol. 2010 Jun;41(2-3):392-409. doi: 10.1007/s12035-010-8137-1. Epub 2010 May 2.

Clinical practice. Early Alzheimer's disease

Mayeux R.

N Engl J Med. 2010 Jun 10;362(23):2194-201. doi: 10.1056/NEJMcp0910236.

Current therapies and new strategies for the management of Alzheimer's disease

Aderinwale OG, Ernst HW, Mousa SA.

Am J Alzheimers Dis Other Demen. 2010 Aug;25(5):414-24. doi: 10.1177/1533317510372372. Epub 2010 Jul 2.

Aspirin in Alzheimer's disease: increased risk of intracerebral hemorrhage: cause for concern?

Thoonsen H, Richard E, Bentham P, Gray R, van Geloven N, De Haan RJ, Van Gool WA, Nederkoorn PJ.

Stroke. 2010 Nov;41(11):2690-2. doi: 10.1161/STROKEAHA.109.576975. Epub 2010 Oct 7.

Current treatments for patients with Alzheimer disease

Osborn GG, Saunders AV.

J Am Osteopath Assoc. 2010 Sep;110(9 Suppl 8):S16-26.

Predicting cognitive decline in Alzheimer's disease: an integrated analysis

Lopez OL, Schwam E, Cummings J, Gauthier S, Jones R, Wilkinson D, Waldemar G, Zhang R, Schindler R.

Alzheimers Dement. 2010 Nov;6(6):431-9. doi: 10.1016/j.jalz.2010.04.003.

Alzheimer's disease amyloid hypothesis at crossroads: where do we go from here?

Saxena U.

Expert Opin Ther Targets. 2010 Dec;14(12):1273-7. doi: 10.1517/14728222.2010.528285.

Factors of error and effort in memory intervention for patients with Alzheimer's disease and amnesic syndrome

Mimura M, Komatsu S.

Psychogeriatrics. 2010 Dec;10(4):179-86. doi: 10.1111/j.1479-8301.2010.00339.x.

NEP-like endopeptidases and Alzheimer's disease [corrected]

Marr RA, Spencer BJ.

Curr Alzheimer Res. 2010 May;7(3):223-9. doi: 10.2174/156720510791050849.

Advanced glycation end products as biomarkers and gerontotoxins - A basis to explore methylglyoxal-lowering agents for Alzheimer's disease?

Krautwald M, Münch G.

Exp Gerontol. 2010 Oct;45(10):744-51. doi: 10.1016/j.exger.2010.03.001. Epub 2010 Mar 6.

Role of biochemical Alzheimer's disease biomarkers as end points in clinical trials

Siemers E, DeMattos RB, May PC, Dean RA.

Biomark Med. 2010 Feb;4(1):81-9. doi: 10.2217/bmm.09.85.

Biochemical markers in Alzheimer's disease clinical trials

Zetterberg H, Mattsson N, Shaw LM, Blennow K.

Biomark Med. 2010 Feb;4(1):91-8. doi: 10.2217/bmm.09.80.

Metabolic-cognitive syndrome: a cross-talk between metabolic syndrome and Alzheimer's disease

Frisardi V, Solfrizzi V, Seripa D, Capurso C, Santamato A, Sancarlo D, Vendemiale G, Pilotto A, Panza F.

Ageing Res Rev. 2010 Oct;9(4):399-417. doi: 10.1016/j.arr.2010.04.007. Epub 2010 May 2.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias